Personalized mRNA vaccine aims to train immune system against ovarian cancer
NCT ID NCT07676890
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial tests a personalized mRNA vaccine called NeoOVIV in people with stage II or III ovarian cancer who have had surgery. The vaccine is designed to teach the immune system to recognize and attack cancer cells. Participants receive the vaccine alongside standard chemotherapy and an immunotherapy drug. The main goals are to check safety and see if the vaccine triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NeoOVIV (personalized mRNA-lipid nanoparticle vaccine)
What this could lead to
If successful, this could point toward a new way to use the immune system to fight ovarian cancer and reduce the risk of recurrence.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not effectiveness. The vaccine may cause side effects or fail to trigger a strong immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.